Drugs / Azelaprag
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06141889 | Nov 2023 → Jan 2024 | — | BioAge Labs, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06515418 | Jun 2024 → Feb 2025 | obesity disorder | BioAge Labs, Inc. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-06-21 | BioAge Labs, Inc. | Results BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions bioagelabs.com ↗
The Apelin Receptor Agonist Azelaprag Shows Cardioprotective Effects as Monotherapy and Enhanced Benefits with Semaglutide in a Diet-Induced Obesity Model of Heart Failure with Preserved Ejection Fraction |
| 2024-12-06 | BioAge Labs, Inc. | Results BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity bioagelabs.com ↗ |
| 2024-11-04 | BioAge Labs, Inc. | Results BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024 bioagelabs.com ↗
Our two presentations provide evidence supporting the ability of BioAge’s azelaprag to enhance weight loss when combined with oral appetite suppression mechanisms, and to protect against excess weight gain and provide metabolic benefits as a monotherapy. |
| 2022-12-05 | BioAge Labs, Inc. | Results BioAge Announces Positive Topline Results for BGE-105 in Phase 1b Clinical Trial Evaluating Muscle Atrophy in Older Volunteers at Bed Rest bioagelabs.com ↗
BGE-105 treatment resulted in statistically significant prevention of muscle atrophy relative to placebo in healthy volunteers aged 65 or older after 10 days of strict bed rest. |
All press releases naming this drug 8 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Azelaprag | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06515418 ↗ |
| Known as | BGE-105 | “Oral Azelaprag (BGE-105)” NCT06515418 ↗ |
| Action | Activate | “oral, apelin receptor (APJ) agonist” NCT06141889 ↗ |
| Modality | Small molecule | — CHEMBL4866732 ↗ |
| Route | Oral | “oral, apelin receptor (APJ) agonist” NCT06141889 ↗ |